Chimeric Defensin Proteins for Cancer VaccinesAvailable for licensing is a fusion protein vaccine comprising a defensin peptide fused to a tumor antigen to elicit an immune response effective in treating cancer.
Humans are particularly vulnerable to cancer as a result of an ineffective immunogenic response. Tumor antigens are known to be poorly immunogenic and attempts to elicit immune responses against the antigens specific to tumor cells have been largely unsuccessful. The inventors have developed a cancer vaccine comprising a defensin peptide fused to a tumor antigen to enhance the immunogenicity of the tumor antigen. The inventors have demonstrated in an animal model that chimeric defensing proteins fused to a lymphoma antigen generate a measurable anti-tumor cellular immune response.
Source:
Chimeric Defensin Proteins for Cancer VaccinesLinkback:
https://tubagbohol.mikeligalig.com/index.php?topic=65272.0
Topic: Science News: Chimeric Defensin Proteins for Cancer Vaccines (Read 319 times)